Moleculin Biotech Depreciation & Amortization Growth & History (MBRX)
Moleculin Biotech's depreciation and amortization was $90,000 for fiscal 2025.
View full Moleculin Biotech company overviewMoleculin Biotech annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $90,000 | −$36,000 | −28.57% |
| 2024 | 2024-12-31 | $126,000 | −$1,000 | −0.79% |
| 2023 | 2023-12-31 | $127,000 | −$3,000 | −2.31% |
| 2022 | 2022-12-31 | $130,000 | −$34,000 | −20.73% |
| 2021 | 2021-12-31 | $164,000 | −$36,000 | −18.00% |
| 2020 | 2020-12-31 | $200,000 | $1,000 | +0.50% |
| 2019 | 2019-12-31 | $199,000 | $131,000 | +192.65% |
| 2018 | 2018-12-31 | $68,000 | $50,000 | +277.78% |
| 2017 | 2017-12-31 | $18,000 | $12,000 | +200.00% |
| 2016 | 2016-12-31 | $6,000 | — | — |
Moleculin Biotech quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8,000 | −$21,000 | −72.41% |
| Q1 2026 | 2026-03-31 | $8,000 | −$23,000 | −74.19% |
| Q4 2025 | 2025-12-31 | $9,000 | — | — |
| Q3 2025 | 2025-09-30 | $21,000 | −$10,000 | −32.26% |
| Q2 2025 | 2025-06-30 | $29,000 | −$2,000 | −6.45% |
| Q1 2025 | 2025-03-31 | $31,000 | −$1,000 | −3.13% |
| Q3 2024 | 2024-09-30 | $31,000 | −$1,000 | −3.13% |
| Q2 2024 | 2024-06-30 | $31,000 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $32,000 | $2,000 | +6.67% |
| Q3 2023 | 2023-09-30 | $32,000 | $0 | 0.00% |
| Q2 2023 | 2023-06-30 | $31,000 | −$3,000 | −8.82% |
| Q1 2023 | 2023-03-31 | $30,000 | −$2,000 | −6.25% |
| Q3 2022 | 2022-09-30 | $32,000 | −$9,000 | −21.95% |
| Q2 2022 | 2022-06-30 | $34,000 | −$10,000 | −22.73% |
| Q1 2022 | 2022-03-31 | $32,000 | −$12,000 | −27.27% |
| Q3 2021 | 2021-09-30 | $41,000 | −$16,000 | −28.07% |
| Q2 2021 | 2021-06-30 | $44,000 | −$8,000 | −15.38% |
| Q1 2021 | 2021-03-31 | $44,000 | −$2,000 | −4.35% |
| Q3 2020 | 2020-09-30 | $57,000 | $6,000 | +11.76% |
| Q2 2020 | 2020-06-30 | $52,000 | $3,000 | +6.12% |
| Q1 2020 | 2020-03-31 | $46,000 | −$2,000 | −4.17% |
| Q3 2019 | 2019-09-30 | $51,000 | $40,000 | +363.64% |
| Q2 2019 | 2019-06-30 | $49,000 | $42,000 | +600.00% |
| Q1 2019 | 2019-03-31 | $48,000 | $40,000 | +500.00% |
| Q3 2018 | 2018-09-30 | $11,000 | $6,000 | +120.00% |
| Q2 2018 | 2018-06-30 | $7,000 | $2,000 | +40.00% |
| Q1 2018 | 2018-03-31 | $8,000 | $4,000 | +100.00% |
| Q3 2017 | 2017-09-30 | $5,000 | $4,000 | +400.00% |
| Q2 2017 | 2017-06-30 | $5,000 | $4,000 | +400.00% |
| Q1 2017 | 2017-03-31 | $4,000 | $4,000 | — |
| Q3 2016 · Sep 30 | 2016-09-30 | $1,000 | $1,000 | — |
| Q2 2016 | 2016-06-30 | $1,000 | — | — |
| Q1 2016 | 2016-03-31 | $0 | — | — |
| Q3 2016 · Sep 30 | 2015-09-30 | $0 | — | — |
Moleculin Biotech depreciation and amortization trends
Over the last five fiscal years, Moleculin Biotech's depreciation and amortization decreased from $200,000 to $90,000, a change of −$110,000. The latest reported quarter, Q2 2026, shows $8,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Moleculin Biotech source filings ↗